BTIG Research reaffirmed their hold rating on shares of Illumina (NASDAQ:ILMN) in a research report sent to investors on Tuesday morning.

ILMN has been the topic of several other research reports. Barclays boosted their price objective on shares of Illumina from $150.00 to $185.00 and gave the stock an equal weight rating in a report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Illumina from a hold rating to a buy rating and set a $229.00 price objective on the stock in a report on Friday, October 27th. Canaccord Genuity restated a buy rating and set a $230.00 price objective (up previously from $215.00) on shares of Illumina in a report on Thursday, October 12th. Piper Jaffray Companies restated an overweight rating and set a $226.00 price objective (up previously from $202.00) on shares of Illumina in a report on Monday, October 9th. Finally, Janney Montgomery Scott upgraded shares of Illumina from a sell rating to a neutral rating in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $220.13.

Illumina (ILMN) traded down $3.30 during trading hours on Tuesday, hitting $241.42. 1,139,900 shares of the stock traded hands, compared to its average volume of 1,167,010. Illumina has a one year low of $156.50 and a one year high of $248.97. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The company has a market cap of $35,420.00, a P/E ratio of 45.55, a price-to-earnings-growth ratio of 3.30 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. During the same quarter in the previous year, the firm posted $0.97 EPS. The business’s revenue was up 17.6% compared to the same quarter last year. research analysts forecast that Illumina will post 3.76 EPS for the current fiscal year.

In related news, SVP Oene Mark Van sold 1,250 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $207.76, for a total value of $259,700.00. Following the sale, the senior vice president now owns 11,691 shares of the company’s stock, valued at $2,428,922.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $224.50, for a total transaction of $32,552.50. Following the completion of the sale, the senior vice president now directly owns 7,411 shares in the company, valued at approximately $1,663,769.50. The disclosure for this sale can be found here. In the last three months, insiders sold 137,671 shares of company stock worth $29,485,768. 0.89% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Advisory Services Network LLC boosted its position in Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares in the last quarter. Dupont Capital Management Corp acquired a new position in Illumina in the third quarter valued at about $153,000. Patten Group Inc. boosted its position in Illumina by 71.1% in the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after buying an additional 615 shares in the last quarter. West Coast Financial LLC acquired a new position in Illumina in the third quarter valued at about $216,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new position in Illumina in the second quarter valued at about $226,000. Hedge funds and other institutional investors own 91.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Illumina (ILMN) Given “Hold” Rating at BTIG Research” was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/illumina-ilmn-given-hold-rating-at-btig-research/1810814.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.